214 results about "PAPILLOMAVIRUS HUMAN" patented technology

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein—HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.

The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection.

The invention relates to monoclonal antibodies and antigen binding fragments thereof, which can have a broad spectrum combination with human papilloma virus (HPV) L1 protein, coding of the sequences of the monoclonal antibodies and the antigen binding fragments thereof, generation of cell strains of the monoclonal antibodies and the antigen binding fragments thereof, and methods and applications of the monoclonal antibodies and the antigen binding fragments thereof on diagnosis, prevention or treatment.

The present invention relates to genes of the Pichia pastoris expression codon-optimized main capsid protein L1 of human papilloma virus types 52,31 and 45, a vector containing the genes, a strain, a preparation method, and an expression method thereof.

The invention relates to a polypeptide, in particular to a human papilloma virus coat protein L1 short peptide and relative application. The invention is characterized in that the sequence of the human papilloma virus coat protein L1 short peptide is N-EVNLKEKFSADLDQFPLGRKFLLQAGLKAK-C. The invention can simultaneously induce human papilloma virus coat protein L1 short peptide with immunity reaction on high risk type and low risk type, which can induce and form the antibody for various human papilloma virus (HPV) and coat protein (HPV L1), to check various HPV or HPV L1, while the antibody can be used in biological pharmaceutical engineering, to purify and prepare various HPV or HPV L1.

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E7_11-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

The invention provides a human papillomavirus HPV DNA fragment, a mix primer for human papillomavirus HPV DNA detection and/ or parting and application thereof. The mixed primer can specifically amplify to obtain one or a plurality of DNA sequences from HPV6, HPV 11, HPV 16, HPV 18, HPV 26, HPV 31, HPV 33, HPV 35, HPV 39, HPV 40, HPV 42, HPV 43, HPV 44, HPV45, HPV 51, HPV 52, HPV 53, HPV 54, HPV 55, HPV 56, HPV 58, HPV 59, HPV 61, HPV 66, HPV 68, HPV 70, HPV 72, HPV 73, HPV 81, HPV 82 and HPV 83, can be used for the human papillomavirus HPV DNA detection and/ or parting and prepared into a PCR kit. The invention can detect common types of HPV at a time, greatly improve the HPV detection efficiency, overcome the defect of missed detection of latent infection by a serology and IHC detection method, realize early diagnosis of HPV diseases, and is suitable for clinical HPV gene detection and parting and guides prevention and cure of cervical carcinoma.

The invention discloses human papillomavirus (HPV) antigen formulations which prevent protein aggregation and show prolonged stability as aqueous solutions. These formulations comprise a salt (such as sodium chloride) and a non ionic surfactant (Polysorbate 80 such as Tween 803) in physiologically acceptable concentrations.

The present invention relates to novel methods for producing an enhanced immune response to an immunogen in a subject via the co-administration of a CD40 agonist and a GM-CSF agent.

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

The invention discloses a detection kit, detection system and detection method for 19 high-risk HPVs. The 19 high-risk HPVs comprise HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82. According to the invention, a plurality of general primers are employed for amplification of target fragments, and specific fluorescence probes are used for real-time detection of the amplified fragments; since the general primers are employed, the primer amount of the system and complexity of the system are reduced, cost is saved, and all the high risk types are detected through combined action of 10 primers; and 20 specific fluorescence probes are used to distinguish different types. With the detection kit, detection system and detection method provided by the invention, the 19 high-risk HPVs can be detected in a reaction tube; high sensitivity and good specificity are obtained; operation is simple and fast; and for patients, screening cost is saved.

The invention provides an immune colloidal gold test card for testing high-risk type human papillomavirus. A test strip thereof consists of a back lining, a sample pad, a combining pad, an NC membrane and a water-absorbing pad; the upper middle part of the back lining is provided with the NC membrane; the two ends of the NC membrane are respectively connected with the combining pad and water-absorbing pad in a neighboring way; the sample pad is arranged above the combining pad; a gold-labelled antibody G-Ab1 is sprayed on the combining pad; the coated gold-labelled antibody G-Ab1 is the monoclonal antibody of the high-risk type human papillomaviru virus HPV16; and the NC membrane is respectively sprayed with the polyclonal antibody Ab2 of the high-risk type human papillomaviru virus HPV16 and the antibody of the gold-labelled antibody, namely the IgG antibody of a rabbit antimouse. The invention applies the technology of immune colloidal gold into the quick testing of the high-risk type human papillomaviru virus; moreover, the test strip for quick testing the high-risk type human papillomaviru virus does not need a test device, thus being convenient for the application to the clinic quick diagnosis and suitable to hospitals of various grades to screen cervical carcinoma.

Cervical cancer cells and HPV⁺ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.